Compare OSS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | BIVI |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.4M | 10.8M |
| IPO Year | 2018 | N/A |
| Metric | OSS | BIVI |
|---|---|---|
| Price | $7.10 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 599.1K | 74.6K |
| Earning Date | 11-05-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,264,017.00 | N/A |
| Revenue This Year | $18.00 | N/A |
| Revenue Next Year | $9.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.33 | N/A |
| 52 Week Low | $1.85 | $1.16 |
| 52 Week High | $7.92 | $25.76 |
| Indicator | OSS | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 27.36 |
| Support Level | $6.50 | $1.40 |
| Resistance Level | $7.77 | $1.46 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 42.25 | 9.47 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.